Hess G - Search Results

1

Rituximab in the treatment of non-Hodgkin's lymphoma.

Hauptrock B, Hess G. Hauptrock B, et al. Among authors: hess g. Biologics. 2008 Dec;2(4):619-33. doi: 10.2147/btt.s3235. Biologics. 2008. PMID: 19707443 Free PMC article.

2

Effect of rituximab on the long-term outcome after high-dose therapy for relapsed B-cell non-Hodgkin's lymphoma.

Hess G, Flohr T, Kolbe K, Bonn S, Schuler M, Derigs HG, Huber C. Hess G, et al. Ann Hematol. 2006 Nov;85(11):769-79. doi: 10.1007/s00277-006-0157-6. Epub 2006 Aug 1. Ann Hematol. 2006. PMID: 16896912 Clinical Trial.

3

Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes.

Hess G, Smith SM, Berkenblit A, Coiffier B. Hess G, et al. Semin Oncol. 2009 Dec;36 Suppl 3:S37-45. doi: 10.1053/j.seminoncol.2009.10.012. Semin Oncol. 2009. PMID: 19963099 Review.

4

Temsirolimus for the treatment of mantle cell lymphoma.

Hess G. Hess G. Expert Rev Hematol. 2009 Dec;2(6):631-40. doi: 10.1586/ehm.09.57. Expert Rev Hematol. 2009. PMID: 21082954 Review.

5

Checkpoint Inhibition in Non-Hodgkin's Lymphoma.

Heß G. Heß G. Oncol Res Treat. 2017;40(11):662-672. doi: 10.1159/000481888. Epub 2017 Oct 23. Oncol Res Treat. 2017. PMID: 29065421 Review.

6

Life-threatening disseminated enterovirus infection during combined rituximab and ibrutinib maintenance treatment for mantle cell lymphoma: a case report.

Higer M, Cana D, Podlech J, Schadmand-Fischer S, Schwarting A, Teschner D, Theobald M, Wölfel T, Hess G. Higer M, et al. Among authors: hess g. J Med Case Rep. 2020 Aug 28;14(1):135. doi: 10.1186/s13256-020-02457-y. J Med Case Rep. 2020. PMID: 32859260 Free PMC article.

7

Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia.

Heidel F, Lipka DB, von Auer C, Huber C, Scharrer I, Hess G. Heidel F, et al. Among authors: hess g. Thromb Haemost. 2007 Feb;97(2):228-33. doi: 10.1160/th06-09-0499. Thromb Haemost. 2007. PMID: 17264951

8

High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).

Weide R, Hess G, Köppler H, Heymanns J, Thomalla J, Aldaoud A, Losem C, Schmitz S, Haak U, Huber C, Unterhalt M, Hiddemann W, Dreyling M; German Low Grade Lymphoma Study Group. Weide R, et al. Among authors: hess g. Leuk Lymphoma. 2007 Jul;48(7):1299-306. doi: 10.1080/10428190701361828. Leuk Lymphoma. 2007. PMID: 17613757 Clinical Trial.

9

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.

Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, Laurell A, Offner F, Strahs A, Berkenblit A, Hanushevsky O, Clancy J, Hewes B, Moore L, Coiffier B. Hess G, et al. J Clin Oncol. 2009 Aug 10;27(23):3822-9. doi: 10.1200/JCO.2008.20.7977. Epub 2009 Jul 6. J Clin Oncol. 2009. PMID: 19581539 Clinical Trial.

10

Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?

Kirschey S, Wagner S, Hess G. Kirschey S, et al. Among authors: hess g. Clin Med Insights Oncol. 2012;6:153-64. doi: 10.4137/CMO.S7327. Epub 2012 Mar 12. Clin Med Insights Oncol. 2012. PMID: 22550404 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

870 results

Search Page